Post-transplant Lymphoproliferative Disease
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BioTherapeutics IncVA - Blacksburg
1 program1
Autologous EBV-CTL transduced with vector SFG-CNA12Phase 11 trial
Active Trials
Genetix BiotherapeuticsMA - Somerville
1 programAutologous EBV-CTL transduced with vector SFG-CNA12PHASE_1
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BioTherapeutics IncAutologous EBV-CTL transduced with vector SFG-CNA12
Clinical Trials (1)
Total enrollment: 18 patients across 1 trials
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Start: May 2019Est. completion: May 202518 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.